Dr Kimberly Stegmaier

The Stegmaier laboratory develops and integrates “omic” approaches to identify new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. The laboratory has focused on pediatric malignancies notable for the aberrancy of differentiation and/or oncogenic activation of transcription factors: the acute leukemias, neuroblastoma, and Ewing sarcoma.

Dr. Stegmaier is an Associate Professor of Pediatrics at Harvard Medical School, a Principal Investigator at Dana-Farber Cancer Institute (DFCI), and an Institute Member of the Broad Institute. She is the Co-director of the Pediatric Hematologic Malignancy Program and an attending physician providing clinical care in Pediatric Oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital. She has won numerous awards, including recently the A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School, the SPR Young Investigator Award, the Sir William Osler Young Investigator Award from the Interurban Clinical Club and a SU2C Innovative Research Grant.

Dr. Stegmaier received her undergraduate degree from Duke University, medical degree from Harvard Medical School, and trained in Pediatrics and Pediatric Hematology/Oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute.